Vactosertib in Osteosarcoma

Vactosertib in Osteosarcoma

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description

This study involves a taking a study drug called vactosertib by mouth. The overall goal of this study is to find out if vactosertib is a safe and effective treatment for adolescents and adults with recurrent, refractory or progressive Osteosarcoma.

Eligibility and criteria
IRB Number:
22-020384
Eligible age range:
14 years - 24 years
Clinical trial phase:
Phase I
Phase II
Official title:
A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.